×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SMMT – summit therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SMMT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/14
10:00 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
1/14
08:42 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/13
01:36 pm
smmt
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
Low
Report
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
1/13
12:37 am
smmt
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
1/12
12:16 pm
smmt
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]
Low
Report
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]
1/12
06:31 am
smmt
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) [Yahoo! Finance]
High
Report
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) [Yahoo! Finance]
1/12
06:17 am
smmt
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC [Yahoo! Finance]
High
Report
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC [Yahoo! Finance]
1/12
06:15 am
smmt
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
High
Report
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
04:02 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 08 Filed by: Anand Bhaskar
Low
Report
Form 4 Summit Therapeutics Inc. For: Jan 08 Filed by: Anand Bhaskar
1/12
07:43 am
smmt
Form 8-K Summit Therapeutics Inc. For: Jan 12
High
Report
Form 8-K Summit Therapeutics Inc. For: Jan 12
1/6
07:53 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Zanganeh Mahkam
Low
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Zanganeh Mahkam
1/6
07:50 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: DUGGAN ROBERT W
Low
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: DUGGAN ROBERT W
1/6
06:55 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Booth Robert F.
Low
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Booth Robert F.
1/6
06:53 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Xia Yu
Low
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Xia Yu
1/6
06:50 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Huber Jeff
Low
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Huber Jeff
1/6
06:45 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Ronaghi Mostafa
Low
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Ronaghi Mostafa
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Summit Appoints Robert W. Duggan as Chief Executive Officer
27.7%
3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%
6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%
12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%
12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%
3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%
10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%
2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%
12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%
3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%
6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%
12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%
12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%
3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%
10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%
2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%
12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%
TOP News Decliners
5/1
SUMMIT THERAPEU/S (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
-12.0%
10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%
12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%
10/11 Half-year report -5.7%
10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%
5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%
11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%
1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%
4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%
7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%
10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%
12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%
10/11 Half-year report -5.7%
10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%
5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%
11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%
1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%
4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%
7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: